US 20210292338A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0292338 A1**

SEGER et al. (43) **Pub. Date: Sep. 23, 2021**

(54) **INHIBITORS OF ERK NUCLEAR TRANSLOCATION**

(71) Applicants: **Yeda Research and Development Co. Ltd.**, Rehovot (IL); **Universitat de Barcelona**, Barcelona (ES); **Institució Catalana de Recerca I Estudis Avançats**, Barcelona (ES)

(72) Inventors: **Rony SEGER**, Rehovot (IL); **Karen FLORES**, Rehovot (IL); **Xavier BARRIL ALONSO**, Barcelona (ES); **Carlos GALDEANO CANTADOR**, Barcelona (ES)

(73) Assignees: **Yeda Research and Development Co. Ltd.**, Rehovot (IL); **Universitat de Barcelona**, Barcelona (ES); **Institució Catalana de Recerca I Estudis Avançats**, Barcelona (ES)

(21) Appl. No.: **17/337,570**

(22) Filed: **Jun. 3, 2021**

Related U.S. Application Data

(63) Continuation of application No. PCT/IL2019/051326, filed on Dec. 3, 2019.

(60) Provisional application No. 62/774,360, filed on Dec. 3, 2018.

Publication Classification

(51) **Int. Cl.**

C07D 498/04	(2006.01)
A61K 45/06	(2006.01)
A61P 35/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07D 498/04*** (2013.01); ***A61P 35/00*** (2018.01); ***A61K 45/06*** (2013.01)

(57) **ABSTRACT**

Described herein are compounds having Formula I or Formula II:

Formula I



Formula II



wherein each dashed line independently represents a saturated or unsaturated bond; R_1 and R'_1 are aryl or heteroaryl as defined herein; and R_2 and R'_2 are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula I or Formula II. The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.

Specification includes a Sequence Listing.